Boston Scientific Corporation (NYSE:BSX) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Boston Scientific Corporation (NYSE:BSX) have received an average recommendation of “Moderate Buy” from the twenty-six research firms that are covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $93.9130.

A number of analysts recently weighed in on BSX shares. Barclays cut their target price on shares of Boston Scientific from $124.00 to $96.00 and set an “overweight” rating on the stock in a research note on Thursday, April 23rd. Stifel Nicolaus cut their target price on shares of Boston Scientific from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Tuesday, April 21st. Raymond James Financial restated an “outperform” rating and set a $88.00 target price (down from $97.00) on shares of Boston Scientific in a research note on Monday, March 30th. Weiss Ratings lowered shares of Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, February 4th. Finally, Truist Financial cut their target price on shares of Boston Scientific from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Thursday, April 23rd.

Boston Scientific Stock Down 4.7%

Shares of BSX opened at $53.89 on Friday. The stock has a market capitalization of $80.08 billion, a PE ratio of 22.55, a P/E/G ratio of 0.99 and a beta of 0.62. Boston Scientific has a 1 year low of $53.63 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.08 and a current ratio of 1.90. The company’s 50-day simple moving average is $65.95 and its 200-day simple moving average is $83.68.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Analysts forecast that Boston Scientific will post 3.38 earnings per share for the current fiscal year.

Institutional Trading of Boston Scientific

Large investors have recently made changes to their positions in the company. Financial Consulate Inc. purchased a new stake in shares of Boston Scientific during the third quarter worth approximately $25,000. Murphy & Mullick Capital Management Corp increased its stake in Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares during the last quarter. FWL Investment Management LLC purchased a new position in Boston Scientific in the second quarter valued at approximately $26,000. Swiss RE Ltd. purchased a new position in Boston Scientific in the fourth quarter valued at approximately $26,000. Finally, Garton & Associates Financial Advisors LLC purchased a new position in Boston Scientific in the fourth quarter valued at approximately $26,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.